Graves' disease.
By R. Bahn, E. Levy, L. Wartofsky. Journal of Clinical Endocrinology and Metabolism, 2007
1,513 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/af03d6ee834b26e5d6f3438cddfff74450f06968
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- G. Kahaly
- L. Bartalena
- L. Hegedüs
- L. Leenhardt
- S. Pearce
- K. Poppe
Citations in the corpus
- THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY. (2021, neutral): “…European Thyroid Association (ETA)/European Group on GO (EUGOGO) guidelines for the management of GO (8), several relevant studies have been published, particularly randomized clinical trials (RCTs) of newer biological agents for the treatment of moderate-to-severe and active GO (1, 9, 10, 11, 12).”
- 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism (2018, methodology): “…autoimmune thyroid disease should have their TSH-R-Ab serum levels measured at the first presentation of pregnancy using either a sensitive binding or a functional cell-based bioassay, and, DOI: 10.1159/000490384 if they are elevated, again at 18–22 weeks of gestation [5, 21–23, 43, 44, 149, 150].”